Evaluation of immune efficacy of recombinant PRRSV vectored vaccine rPRRSV-E2 in piglets with maternal derived antibodies

• Published in: Veterinary microbiology 2020-09, Vol.248, p.108833-108833, Article 108833
• Main Authors: Gao, Fei, Jiang, Yifeng, Li, Guoxin, Li, Liwei, Zhang, Yujiao, Yu, Lingxue, Zheng, Hao, Tong, Wu, Zhou, Yanjun, Liu, Changlong, Shan, Tongling, Yu, Hai, Kong, Ning, Chen, Pengfei, Tong, Guangzhi
• Format: Article
• Language: English
• Subjects: Animal diseases; Antibodies; CSFV; E2 protein; Fever; Hog cholera; Hogs; Immune response; Immunization; Maternal derived antibody; PRRSV; rPRRSV-E2; Vaccines; Viremia
• ISSN: 0378-1135; 1873-2542
• DOI: 10.1016/j.vetmic.2020.108833

•rPRRSV-E2 is a marker vaccine for CSFV.•rPRRSV-E2 is promising as a virus-vectored vaccine against both HP-PRRSV and CSFV infection in swine herds by single vaccination.•Maternal derived antibodies (MDAs) do not interfere with the immune efficacy of rPRRSV-E2. Currently live attenuated porcine reproductive and respiratory syndrome (PRRS) and classical swine fever (CSF) vaccines are widely used in Chinese swine herds. However, the mutual effects of vaccination procedures and severe stress caused by successive vaccinations harm piglets and make it difficult to stimulate robust and effective immune responses. In our previous study, a recombinant PRRS virus (PRRSV) vectored vaccine candidate rPRRSV-E2, which expresses CSF virus (CSFV) E2 protein, has been demonstrated being able to protect piglets against lethal challenge of highly-pathogenic (HP)-PRRSV and CSFV. In this study, we determine whether preexisting maternally derived antibodies (MDA) interfere with the immune efficacy of rPRRSV-E2. 8 experimental groups of piglets, with or without PRRSV MDAs or CSFV MDAs were immunized with a single dose of 105 TCID50 rPRRSV-E2 or DMEM and challenged with HP-PRRSV or CSFV. Clinical characteristics, PRRSV- or CSFV-specific antibodies, viremia and pathological changes were monitored, examined and analyzed. The results showed that rPRRSV-E2-vaccinated piglets, either with or without MDAs directed against PRRSV or CSFV were completely protected from the lethal challenge of HP-PRRSV or CSFV. These results demonstrate that the MDAs do not interfere with the immune efficacy of rPRRSV-E2, which indicates that rPRRSV-E2 could have great significance in the effective prevention and control of HP-PRRSV and CSFV.